Asarfi Hospital Ltd

Asarfi Hospital has reached an all-time high, reflecting a remarkable phase in its market journey. The stock’s recent performance underscores its strong presence in the hospital sector, with notable gains and financial metrics that highlight its current standing.

Asarfi Hospital has reached a significant milestone by hitting a new 52-week high of Rs.193.8 today, marking a notable moment in the stock’s recent performance and momentum within the hospital sector.

Asarfi Hospital has reached a significant milestone by hitting a new 52-week high of Rs.193.8, marking a notable achievement in its stock performance amid a mixed market environment.

Asarfi Hospital has reached a significant milestone by hitting a new 52-week high of Rs.193.8, marking a notable achievement in its stock performance. This peak reflects the stock's strong momentum over the past year, supported by robust financial metrics and consistent quarterly results.

Asarfi Hospital has reached an all-time high stock price, reflecting its strong financial health and operational success. The company reported a significant net profit growth and record net sales for the recent quarter. Its low debt-to-EBITDA ratio further highlights its effective financial management and robust market position.

Asarfi Hospital has achieved a new 52-week high, reflecting strong market performance and momentum. The stock has significantly outperformed its sector and delivered impressive annual returns. The company reported substantial net profit growth and record sales, alongside a favorable debt-to-EBITDA ratio, indicating solid financial health.

Asarfi Hospital achieved a new 52-week high of Rs. 186.5 on November 17, 2025, reflecting strong performance with an 11.33% gain over two days. The company reported a 34.38% increase in net profit and a low Debt to EBITDA ratio, showcasing robust financial health and significant returns over the past year.

Asarfi Hospital has achieved a new 52-week high, reflecting strong performance as it outpaces its sector. The stock has shown a robust upward trend, gaining over 11% in two days and trading above key moving averages. Its one-year performance significantly exceeds that of the broader market.

Asarfi Hospital has achieved a new 52-week high, reflecting strong performance in the microcap sector. The company reported a significant net profit growth and record high net sales, alongside a favorable Debt to EBITDA ratio, indicating robust financial health and stability within the hospital industry.

Asarfi Hospital has reached an all-time high, showcasing strong financial health and operational success. The company reported a 34.38% net profit growth and record net sales of Rs 44.89 crore. Its effective debt management and robust return on capital employed further highlight its favorable position in the hospital industry.

Asarfi Hospital has recently adjusted its financial evaluation, showcasing strong performance for the quarter ending September 2025. Key metrics, including net sales and profit after tax, reached new highs, while the company demonstrated solid debt servicing capabilities. Overall, its financial outlook remains robust amid market challenges.

Asarfi Hospital has adjusted its valuation, revealing a price-to-earnings ratio of 31.38 and a price-to-book value of 4.07. The hospital reports a return on capital employed of 8.65% and a return on equity of 12.97%, reflecting its profitability and operational efficiency compared to industry peers.

Asarfi Hospital achieved a new 52-week high on November 14, 2025, reflecting strong stock performance and impressive growth over the past year. The company reported significant net profit and sales increases, while maintaining a solid financial position with low debt and favorable valuation metrics.

Asarfi Hospital has reached a significant milestone, achieving an all-time high on November 14, 2025. The company reported record net sales of Rs 44.89 crore and a 34.38% increase in net profit. Its strong financial management is reflected in a low debt-to-EBITDA ratio and solid return on capital employed.